Product Information
NYLIA 7-7-7-28 TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.2161 per EA under NDC 65862089788. Its NADAC has been published 269 times since Aug 11, 2021.
FDA first approved this application on Oct 21, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
65862089788
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA207054FDA Approved
10/21/2016
TE Code
AB
On Market Since
10/21/2016
Price Statistics
The NADAC for NYLIA 7-7-7-28 TABLET has been published 269 times since Aug 11, 2021, and over the history we have for it it has declined 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2161 per EA |
|---|---|
| All-time high | $0.5336 (Feb 15, 2023) |
| All-time low | $0.1916 (Nov 20, 2024) |
| 52-week high | $0.2985 |
| 52-week low | $0.2161 |
| Median price | $0.2903 |
| Average price | $0.3085 |
| Largest weekly change | -36.8% (May 17, 2023) |
| Weeks tracked | 269 |
| Tracking since | Aug 11, 2021 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NYLIA 7-7-7-28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NYLIA 7-7-7-28 TABLET, manufactured by Aurobindo Pharma Limited, is $0.2161 per EA (NDC 65862089788), effective Sep 30, 2026.
How has the price of NYLIA 7-7-7-28 TABLET changed over time?
Over the history we have for it, the NADAC for NYLIA 7-7-7-28 TABLET has declined 42.1%. It has been tracked across 269 weekly CMS publications since Aug 11, 2021.
What are the highest and lowest recorded NADAC prices for NYLIA 7-7-7-28 TABLET?
Since Aug 11, 2021, the NADAC for NYLIA 7-7-7-28 TABLET has ranged from a low of $0.1916 (Nov 20, 2024) to a high of $0.5336 (Feb 15, 2023), with a median of $0.2903 per EA.
Are there cheaper alternatives to NYLIA 7-7-7-28 TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYLIA 1-35 28 TABLET, is $0.2026 per EA — about 6% below NYLIA 7-7-7-28 TABLET.
Who manufactures NYLIA 7-7-7-28 TABLET?
NYLIA 7-7-7-28 TABLET (NDC 65862089788) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.